Replies to post #250827 on Biotech Values

[DewDiligence]

APLS refinances debt:

https://finance.yahoo.com/news/apellis-pharmaceuticals-refinances-existing-debt-120000044.html

New $475M credit lines expiring in 2030 enable APLS to pay off debt due in 2027.

APLS’ Syfovre is not an especially good drug (#msg-173940338), but there is apparently no shortage of lenders to refinance debt of companies with FDA-approved products.